The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study

Andrea Calcagno1,*†, Jessica Cusato1,†, Christine Sekaggya-Wiltshire2, Amrei von Braun3, Ilaria Motta1, Grace Turyasingura3, Barbara Castelnuovo2, Jan Fehr4,5, Giovanni Di Perri1 and Mohammed Lamorde2

Unsatisfactory treatment outcomes have been reported in patients coinfected with HIV/tuberculosis (TB). The aim of this study was to assess the influence of single-nucleotide polymorphisms (SNPs) in genes encoding for proteins involved in antitubercular drug disposition or effect. A pharmacogenetic study was conducted in Kampala, Uganda, where all analysis was performed. The impact of SNPs on antitubercular drug exposure, adverse events, and treatment outcomes was evaluated in patients coinfected with HIV/TB receiving treatments for both conditions. In 221 participants, N-acetyltransferase 2 (NAT2; rs1799930), solute carrier organic anion transporter family member 1B1 (SLCO1B1; rs4149032), and pregnane X receptor (PXR; rs2472677) variants affected isoniazid exposure in multivariate analysis. Most patients were deemed cured (163; 73.8%), yet PXR 63396TT carriers had a higher probability of death (P = 0.007) and of worsening peripheral neuropathy (P = 0.018). In this exploratory study in Ugandan patients coinfected with HIV/TB, genetic variants in PXR, SLCO1B1, and NAT2 were moderately associated with isoniazid exposure, whereas PXR 63396TT carriers showed worse outcomes.

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
☑ The treatment of tuberculosis (TB) in patients with HIV is challenging and it has been associated with lower success rates as compared to HIV-uninfected patients. Several genetic variants have been associated with antitubercular drug plasma concentrations and liver toxicity, but their use in clinical practice is extremely limited.

WHAT QUESTION DID THIS STUDY ADDRESS?
☑ This study addresses the impact of genetic variants in selected genes involved in drug metabolism or transport on antitubercular drugs' pharmacokinetic profile, liver, or neurological toxicity and outcomes. This was studied in a population of patients with HIV-positive disease with active TB in Uganda.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
☑ The study suggests that genetic variants (assessed in a Uganda-based laboratory) in genes encoding for pregnane X receptor (PXR), organic anion transporter family member 1B1, and N-acetyltransferase 2 are associated with isoniazid exposure. The association of PXR 63396 TT variant with an increased risk of death and worsening peripheral neuropathy is novel but needs to be confirmed in independent studies.

HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
☑ Once confirmed in other studies, these data may support the use of genetic markers for antitubercular tailored treatment in hard-to-treat patients.

With 9.6 million new cases/year and ~ 1.5 million deaths/year, tuberculosis (TB), is one of the leading infectious disease in terms of morbidity and mortality worldwide.1 It is the most frequently occurring opportunistic infection in people living with HIV and it is associated with significant attributable mortality. For example, patients coinfected with HIV/TB have worse treatment outcomes and higher relapse rates compared to HIV-negative patients with TB.2-4 Suboptimal plasma concentrations of anti-TB drugs are commonly found in patients with HIV-positive disease that may be due to unpredictable drug absorption and potential drug–drug interactions.3 Low serum concentrations of antitubercular drugs are associated with slow response and treatment failure, and they

1Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy; 2Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; 3Division of Infectious Diseases and Tropical Medicine, University Hospital Leipzig, University of Leipzig, Leipzig, Germany; 4Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 5Department of Public Health, Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.
*Correspondence: Andrea Calcagno (andrea.calcagno@unito.it)
†Both authors equally contributed to this manuscript.
Received November 7, 2018; accepted February 8, 2019. doi:10.1002/cpt.1403
may contribute to the selection of drug-resistant strains.\textsuperscript{6} A recent analysis in patients coinfected with HIV/TB in Uganda showed that patients with low concentrations of rifampicin (RIF) and isoniazid (INH) were less likely to reach sputum culture conversion before the end of TB treatment or by the end of follow-up (6 months after the completion of treatment).\textsuperscript{7}

Interindividual variability, tissue penetration, and drug–drug interactions are partially explained by genetic variants in genes encoding for drug metabolizing or transporting proteins. Single-nucleotide polymorphisms (SNPs) are the most common genetic variants; they seldom influence protein expression or activity, whereas some genetic variants may affect the risk of developing certain diseases as well as the efficacy and tolerability of several compounds.\textsuperscript{8,9}

One of the first observed genetic variants of clinical consequence was the association between acetylator state (slow vs. fast) and INH toxicity.\textsuperscript{10} Beyond polymorphisms of N-acetyltransferase 2 (\textit{NAT2}) gene, several other SNPs have been associated with anti-TB drugs’ exposure and toxicity. For instance, genetic variants in solute carrier organic anion transporter family member 1B1 (\textit{SLCO1B1}), encoding for organic anion transporter 1B1; SNP, single-nucleotide polymorphism; VDR, vitamin D receptor.

---

**Table 1 Prevalence of genetic variants (SNPs)**

<table>
<thead>
<tr>
<th>Genes/Proteins</th>
<th>\textit{ABCB1}</th>
<th>\textit{SLCO1B1}</th>
<th>\textit{NAT2}</th>
<th>\textit{CYP2B6}</th>
<th>\textit{PXR}</th>
<th>\textit{HNF4\textalpha}</th>
<th>\textit{VDR}</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{rs1045642}</td>
<td>3435</td>
<td>032</td>
<td>+6</td>
<td>516</td>
<td>63396</td>
<td>975</td>
<td>032</td>
</tr>
<tr>
<td>P-\textit{gp}</td>
<td>103</td>
<td>78</td>
<td>97</td>
<td>79</td>
<td>78</td>
<td>151</td>
<td>144</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>114</td>
<td>51.6%</td>
<td>35.7%</td>
<td>35.3%</td>
<td>68.3%</td>
<td>65.2%</td>
<td></td>
</tr>
<tr>
<td>\textit{NAT2}</td>
<td>114</td>
<td></td>
<td></td>
<td>79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>\textit{CYP2B6}</td>
<td>79</td>
<td></td>
<td></td>
<td>78</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>\textit{PXR}</td>
<td>151</td>
<td></td>
<td></td>
<td>144</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>\textit{HNF4\textalpha}</td>
<td>14%</td>
<td></td>
<td></td>
<td>17.2%</td>
<td>18.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>\textit{VDR}</td>
<td>68.3%</td>
<td>65.2%</td>
<td></td>
<td>14%</td>
<td>2.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not available</td>
<td>30</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>221</td>
<td>221</td>
<td>221</td>
<td>221</td>
<td>221</td>
<td>221</td>
<td>221</td>
</tr>
</tbody>
</table>

Genes (first row), SNP accession numbers (second row), and coded proteins (third row) are listed in every column.

---

RESULTS

Two hundred twenty-one samples (from 221 patients out of 268 from the main protocol) were available, and they were included in this analysis (between May 2013 and November 2015). One hundred thirty participants (58.8%) were men; median age and weight were 34 years (interquartile range (IQR) 29–40) and 50.2 kg (IQR 46–57). Baseline and nadir CD4+ cell count were 161 (IQR 45–277) and 154 (IQR 47–267) cells/\textmu L, respectively. The majority of patients fell into World Health Organization stages III (193; 89.8%) and IV (5; 7%). Sputum-positive smears were recorded in 160 patients (72.4%).

Prevalence of genetic variants

\textit{Table 1} depicts the prevalence of the studied genetic variants. The results for \textit{HNF4\textalpha} and \textit{VDR820 SNP} were not available in 30 and 31 patients, respectively. All SNPs were in Hardy–Weinberg equilibrium, except for \textit{SLCO1B1 032 and NAT2'6 SNPs}.

Pharmacokinetics

\textit{C\textsubscript{max}} (maximal plasma concentrations) and areas under the curve between 0 and 4 hours (AUC\textsubscript{0-4}) are shown in \textit{Table 2}. A significant decrease in INH and RIF AUC\textsubscript{0-4} was observed at week 8 (as compared to week 2, \(P = 0.001\) and 0.020, respectively).
We observed a significant correlation between \( \text{NAT2}^*6 \) (higher AUCs), \( \text{SLCO1B1}^*6 \) (lower AUCs), and \( \text{PXR} \); higher AUCs) genetic variants and \( \text{INH C}_{\text{max}} \) and AUC at week 8.

Figure 1 Isoniazid plasma area under the curve 0–4 hours (AUC\textsubscript{0–4}) according to gender and genetic variants in transporters and metabolizing enzymes. Bold horizontal lines represent median values while smaller lines and whiskers depict interquartile ranges. \( \text{NAT2} \), N-acetyltransferase 2; \( \text{PXR} \), pregnane X receptor; \( \text{SLCO1B1} \), solute carrier organic anion transporter family member 1B1.

Table 2 Plasma concentrations of antitubercular drugs and efavirenz at different time points

<table>
<thead>
<tr>
<th>Drug</th>
<th>Week 2</th>
<th>Week 8</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( \text{C}_{\text{max}} )</td>
<td>AUC\textsubscript{0–4}</td>
<td>( \text{C}_{\text{max}} )</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>6,190 (4,248–8,540)</td>
<td>13,591 (6,410–19,400)</td>
<td>6,127 (4,037–8,478)</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>1,827 (1,147–2,450)</td>
<td>3,590 (1,901–5,941)</td>
<td>1,588 (1,065–2,300)</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>2,540 (1,690–3,700)</td>
<td>4,797 (2,288–7,454)</td>
<td>2,880 (1,680–4,150)</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>39,770 (34,112–45,990)</td>
<td>96,390 (45,032–121,161)</td>
<td>37,590 (32,933–43,585)</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>2,845 (2,017–5,504)</td>
<td>3,395 (1,950–5,403)</td>
<td>3,580 (2,068–7,132)</td>
</tr>
</tbody>
</table>

\( \text{C}_{\text{max}} \) (maximal plasma concentrations and area under the curve between 0 and 4 hours (AUC\textsubscript{0–4}) are expressed as ng/mL and described with median values (interquartile ranges). Efavirenz exposure is described through concentrations 12 hours after drug intakes (\( \text{C}_{12} \)).

NA, not applicable because patients were no longer on treatment with ethambutol and pyrazinamide at week 24.

\( P = 0.005, \beta = 0.21, 95\% \text{CI } 0.22–1.25 \) genetic variants were independent predictors of \( \text{INH AUC}_{0–4} \) at week 8.

The percentage of patients showing \( \text{INH C}_{\text{max}} \) above 3,000 ng/mL at week 8 was moderately predicted by genetic variants in \( \text{NAT2}^*6 \) (7.1% (GG) vs. 17.1% (GA) vs. 28.6% (AA), \( P = 0.067 \)), \( \text{SLCO1B1}^*32 \) (19% (TT) vs. 10.5% (TC) vs. 0% (CC), \( P = 0.029 \)), and \( \text{PXR} \) 63396 (8.3% (CC) vs. 11.6% (CT) vs. 27.3% (TT), \( P = 0.066 \)).

We observed no statistically significant association of the other studied SNPs with drug exposures.
Treatment-associated toxicity
Liver toxicity was observed in 77 of 211 participants (36.5%). Alanine aminotransferase (ALT) elevations were mostly mild (32, 15.2% at week 2 and 27, 14.1% at week 8) or moderate (5, 2.4% at week 2 and 1, 0.5% at week 8); grades 3 and 4 were observed in 4 and 3 individuals, respectively.

Any ALT elevation under treatment was more commonly observed in patients with the CC variant in SLCO1B1 gene (53.1% vs. 32.9%, \(P=0.029\), odds ratio (OR) 2.306, 95% CI 1.075–4.948; Figure S2 – left). Additionally, ALT elevations at week 8 were higher in patients with the TT variant in PXR gene (with 4.17%/4.17% vs. 0%/0.59% grades 2/3 elevations, \(P=0.021\)).

In patients with baseline ALT < 40 UI/mL, ALT values had a significantly higher increase in those with the CYP2B6 TT variant (+16 UI/mL (4–29) and a 1.8-fold (0.4–3.6) increase) vs. those with the GG/GT genotypes (+7 UI/mL (−1 + 14) and a 0.4-fold (0–1.5) change; \(P=0.043\) and \(P=0.016\); Figure S2 – right).

Worsening peripheral neurotoxicity was reported in 29 patients (13.7%); the majority was grade 1 (25; 86.2%), whereas few were grade 2 (3, 10.3%), and only one patient presented with grade 3 symptoms (3.4%). It was observed more frequently in patients with the TT variant in PXR gene (26.7% vs. 11.0%, \(P=0.018\), OR 2.944, 95% CI 1.164–7.443; Figure 2).

We observed no statistically significant association of the other studied SNPs with liver toxicity or peripheral neuropathy.

Outcomes
Most patients were deemed cured (163; 73.8%) with very few failures/relapses (7; 3.2%) and default cases (1; 0.5%); we observed 13 deaths (5.9%) and 18 individuals were lost to follow-up (8.1%). Causes of death included worsening opportunistic conditions with potential IRIS (four cases of Cryptococcal meningitis, one massive hemoptysis), sudden cardiac death (1), acute kidney injury (1), sepsis (1), and gastrointestinal bleeding (1), whereas no information was available in four individuals.

In 159 patients with positive baseline sputum smears and negative samples at follow-up, sputum conversion was obtained after a median of 55 (15–57) days. At log-rank analysis using Kaplan–Meier curves, we observed no effect of genetic variants on time to sputum conversion.

Variants in PXR gene were associated with a nonsignificantly lower chance of achieving TB cure (66.7%) with patients presenting a TT genotype at position 6396 vs. individuals with CC/CT alleles (74.9%; \(P=0.342\)); this was driven by a significantly higher probability of death in individuals presenting the TT 6396 SNP in PXR (16.7%) vs. those presenting other variants (4.2%) (\(P=0.007\), OR 4.575, 95% CI 1.388–15.083; Figure 3).

We observed no statistically significant association of the other studied SNPs with treatment-associated outcomes.

DISCUSSION
Globally, treatment of patients co-infected with HIV/TB is complicated by drug-drug interactions, pill burden, adverse events, and poorer outcomes. The efficacy of anti-TB treatment is of utmost importance to prevent the risk of selection and transmission of Mycobacterium tuberculosis resistant strains in the high-risk group of people living with HIV.19

In this study, we observed that genetic variants in genes encoding for proteins implicated in the metabolism and transport may moderately influence the pharmacokinetics, efficacy, and tolerability of drugs used for treating HIV/TB coinfection. If confirmed in studies with a larger sample size and in different settings, these observations may accelerate development of individually tailored
treatments even in limited-resource countries. Of note, all genetic tests were performed in Uganda by trained local laboratory technicians, thus limiting the costs and potential ethical concerns of sending genetic material abroad. We did not include a cost analysis, but the raw cost of analyzing three SNPs on whole blood can be currently estimated at US $28.5 (considering a full 96-well plate for the analysis). Although we are not aware of cost-efficacy analysis considering pharmacogenetic markers, it should be highlighted that the cost of treating patients coinfected with TB/HIV was estimated to be almost double of the amount used for patients with TB.

The pharmacokinetics of anti-TB compounds has been largely studied over time and thresholds have been defined. Several studies have recognized the role of underexposure of one or more compounds and the association of this event with unfavorable outcomes, such as slow response or treatment failure. In the same study population, Sekaggya-Whiltshire and colleagues found a significant association between low concentrations of RIF and INH and delayed culture conversion and concluded that this may have implications for TB transmission. In this pharmacogenetic analysis, we observed that INH exposure (both as AUC and Cmax) could be predicted by gender and by genetic variants in three genes: NAT2, SLCO1B1, and PXR. Although the first two factors (gender and NAT2 genotype) have been repeatedly reported, the other two (PXR and SLCO1B1 genetic variants) are novel findings. It should be noted that, after correcting for multiple comparisons, NAT2 genotype retained a significant effect on INH AUC and Cmax. INH is not known to be a substrate of SLCO1B1, consequently our observation can either be by chance or because the studied SNP in SLCO1B1 can be in linkage disequilibrium with other relevant genetic loci, or this effect can be mediated by RIF intracellular concentrations. The influence of SNPs in SLCO1B1 has been reported in several, but not all, studies, and we were not able to replicate this observation. Among patients with TB, age over 35 years, female gender, elevated pretreatment liver function tests, malnutrition, and HIV infection increase the high-risk of hepatotoxicity. In patients with HIV-positive disease, an additional risk factor is hepatotoxicity associated with antiretroviral drugs: in our study, all patients received EFV that has been linked to a possible, yet uncommon, liver damage. The higher ALT elevation in patients carrying CYP2B6 516TT suggests that higher EFV exposure may contribute to the observed mild hepatic impairment in the patients we enrolled. Additional pharmacological/pharmacogenetic factors have been identified, such as EFV exposure, the presence of less common variants in NAT2, and, recently, in ABCB1 and CYP2B6 genes, whereas the plasma exposure of anti-TB drugs does not seem to be relevant. Although we reported frequent elevation of ALT in patients treated for HIV/TB, they were mostly grade 1 and very few were grades 3 or 4; therefore, our ability to assess clinically relevant hepatic toxicity was low; additionally, we did not collect hepatitis B virus and hepatitis C virus co infections, among the possible concomitant factors in ALT elevations after combination antiretroviral therapy introduction. However, we observed a slightly higher proportion of patients with ALT elevations with the less common variant in SLCO1B1 and a slightly higher severity at 8 weeks in those presenting a less common variant in PXR. The first finding is somehow surprising because a less expressed SLCO1B1 is associated with lower intrahepatic exposure of RIF. Because several studies demonstrate that liver injury is not linked to plasma exposure, our initial hypothesis was that alternative causes (such as hepatic or intracellular concentrations or specific metabolites) may link genetic variants to liver toxicity. On the contrary, PXR has been linked with a slightly more frequent elevation of ALT in patients carrying the less common variant in SLCO1B1.
shown to modulate hepatotoxicity associated with Rifampicin (RIF) and INH therapy in a mouse model. Although the exact mechanism has not been clarified, it may be related to the induction of CYPs (as shown by the presence of anti-INH, anti-CYP2E1, anti-CYP3A4, and anti-CYP2C9 antibodies) or through the PXR-mediated perturbation of heme biosynthesis. When considering patients with normal baseline ALT, we observed that TT genotype in CYP2B6 was associated with a higher increase in liver enzymes; this may be due to the effect on EFV concentrations or to the involvement of CYPs in INH metabolism.

Furthermore, we observed a moderately higher risk of worsening of peripheral neuropathy in patients with less common variants in PXR gene. Previous evidence suggested concomitant factors (such as low CD4 cell count and malnutrition), INH exposure, and NAT2 metabolism as risk factors, although the effect of plasma exposure of anti-TB drugs is less certain. 

The outcomes of TB treatment are relevant for individuals’ cure and for the prevention of the infection spread to others. The effect of adequate plasma exposure of anti-TB drugs is supported by several pieces of evidence, and our colleagues confirmed this in the same cohort in which we studied pharmacogenetics. In patients with less common variants in PXR gene, we observed a three times lower chance of curing TB and a 4.5 times higher risk of death (despite adjusting for multiple comparisons), whereas there was no effect of other SNPs (including vitamin D receptor, previously associated with treatment outcomes). This is a novel finding, and the complexity of PXR influence on cellular mechanisms may explain it. From a pharmacokinetic point of view, PXR regulates the expression of genes encoding several proteins involved in drug metabolism and transport; their expression may vary among organs tissues, and therefore, PXR activation status may have a differential impact (in macrophages vs. lung tissue). P-gp, for instance, is highly expressed in lung tissues and alveolar macrophages, and its expression may be more relevant for pulmonary concentrations rather than plasma levels. In human tissues and in a mouse model, PXR activation has been shown to reduce the effect of RIF. Several pathways leading to inflammatory processes have been shown to be controlled by PXR, thus potentially being variable among individuals in terms of appropriate immune response and microbe killing. The high heterogeneity in causes of death did not allow for exploring the association for specific unfavorable outcomes.

Allele frequency was similar to published data from East Africa for NAT2*6 (26% vs. 24–33) but lower for ABCB1 3435 (8.6% vs. 57–84%), but genetic heterogeneity has been reported to be high among different ethnic groups even within the same region. Yet, allele frequency was intermediate for the three candidate genes (PXR 63396, SLCO1B1 032, and NAT2*6), thus supporting their potential use in this clinical setting. It should be noted that NAT2*6 and SLCO1B1 032 variants were not in Hardy–Weinberg equilibrium, thus suggesting a hypothetical evolutionary benefit that needs to be further confirmed.

The limited sample size (that was driven by the original study sample determination and by available samples) should be acknowledged as a limitation for the study power to detect clinically relevant outcomes. Yet, applying sample-size calculation post hoc with the observed difference in INH AUC between PXR 63396 CC/CT and TT carriers (−1.53 with an SD of 2.33), and using an alpha error of 0.05, a power of 0.89 was obtained.

In conclusion, we observed that genetic variants in PXR affected INH metabolism (along with gender, NAT2, and SLCO1B1 SNPs); we report here a detrimental effect on HIV/TB patients’ survival of the same genetic polymorphism that warrants further studies in independent cohorts.

METHODS

A pharmacogenetic substudy was carried out within the SOUTH cohort study (Study on Outcomes related to TB and HIV drug Concentrations in Uganda). In this prospective observational study, the correlation of anti-TB drug concentrations and clinical response in individuals infected with HIV with new pulmonary TB was investigated. The study was conducted at the Infectious Diseases Institute, Kampala, Uganda, a center of excellence in HIV care and treatment.

Ethics approval was received from the Joint Clinical and Research Centre Institutional Review Board, the Uganda National Council for Science and Technology, and the National Drug Authority. Written informed consent was obtained from all study participants prior to enrollment, and separate consent was obtained for pharmacogenetics study participation. This study was registered at Clinicaltrials.gov (NCT01782950).

The complete SOUTH study protocol is detailed elsewhere. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study
2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
3. Age of ≥ 18 years
4. First episode of pulmonary TB (i.e., proven or highly suspected TB considered for TB treatment) for 6 months anti-TB drugs regimen—2 months RZHE (Rifampin (R) plus Isoniazid (H) plus Pyrazinamide (Z) plus Ethambutol (E)) and 4 months RH (Rifampin (R) plus Isoniazid (H))
5. Confirmed HIV-1 infection

Subjects presenting with any of the following will not be included in the study:

1. Unable to provide informed consent
2. Documented or highly suspected TB infection of any organs/systems other than the lungs requiring TB treatment longer than 6 months
3. Previously treated for a mycobacterial infection (TB or atypical mycobacterial infection, active, or latent)
4. Pregnancy or planned pregnancy within the next year
5. Unwillingness to perform pregnancy test
6. Decompensated liver disease and/or aminotransferases > 5× upper limit of normal
7. Glomerular filtration rate < 50 mL/minute
8. Comorbidities reducing life expectancy to < 1 year (e.g., cancer)
9. Patient wishes to take part in another interventional study

First-line TB treatment was administered according to World Health Organization guidelines consisting of Rifampicin (RIF) 10 mg/kg, INH (5 mg/kg), Ethambutol (15 mg/kg), and Pyrazinamide (20 mg/kg) for 8 weeks, followed by RIF and INH for 16 weeks. In treatment-naïve patients, antiretroviral treatment consisting of tenofovir, lamivudine, and EFV was
started at least 2 weeks after initiation of TB treatment. Patients who were already on antiretroviral treatment at the time of TB diagnosis continued their treatment, whereas patients on nevirapine were switched to EFV to reduce drug–drug interactions. Patients on protease inhibitors received rifabutin instead of RIF and were, therefore, excluded from this analysis.

Serum concentrations of RIF, INH, ethambutol, and pyrazinamide were measured at 1, 2, and 4 hours postdosing. EFV (600 mg) was measured at 12 ± 2 hours postdosing, but the results of genetic variants and EFV exposure have been reported separately.9 Patients with undetectable 2-hour concentrations were excluded from the analysis. The pharmacokinetic analyses were performed with high-performance liquid chromatography, and AUCs were estimated using noncompartmental analysis.

SNPs were analyzed through real-time polymerase chain reaction by allelic discrimination. Genes were selected following the available evidence of an effect of the encoded proteins on antitubercular drugs exposure (P-gp, OATP1B1, and NAT2) or treatment response (vitamin D receptor) on efavirenz exposure (CYP2B6) or on the theoretical intracellular pathways that have been involved in drug metabolism and activity (PXR and HNF4–α).

The following genes SNPs were studied: ABCB1 3435 C>T (rs1045642), SLCO1B1 3’ UTR T>C (rs4149032), NAT2 698 G>A (rs1799930), CYP2B6 516 G>T (rs3745274), PXR 63396 C>T (rs2472677), HNF4a 975 C>G (rs1884613), and VDR Cdx2 A>G (rs11568820). They were selected following previous data involving either a significant effect on the enzyme expression/activity, on pharmacokinetics, or treatment effect in patients with TB and taking into account the prevalence of less common variants. For instance, NAT2’6 was chosen because the reported prevalence of allele frequency in East Africa was 24–33%.40

We were not able to assess the haplotype frequency in Uganda for several genes because data are limited (no published study reported the prevalence of PXR SNPs) and genetic heterogeneity wide.

All pharmacokinetic and pharmacogenetic analyses were performed at the Infectious Diseases Institute research translational laboratory in Kampala; SNP results were available after the study completion and, therefore, retrospectively analyzed.

Severity of hepatotoxicity was graded according to the National Institutes of Health Division of AIDS toxicity tables as follows: ALT 40–119, mild/grade 1; ALT 120–199, moderate/grade 2; and ALT ≥ 200, severe/grade 3. Peripheral neuropathy was evaluated clinically and reported in those patients complaining of worsening symptoms under treatment and graded according to Division of Acquired Immunodeficiency Syndrome toxicity tables.

Descriptive data are presented as median with IQR for continuous variables, and as numbers and percentages for categorical variables. AUCs were calculated using Kinetic version 5.1 SP1 (Thermo Fisher Scientific, Waltham, MA). Kruskal–Wallis test by ranks, the nonparametric version of analysis of variance, was used to test equality of AUCs medians among groups. The nonparametric version of Kruskal–Wallis test by ranks, the nonparametric version of analysis of variance, was used to test equality of AUCs medians among groups.

ACKNOWLEDGMENTS

Preliminary results were presented in the e-Poster section at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017 in Vienna, Austria. The authors acknowledge the contributions of the study participants, staff, and management of the Infectious Diseases Institute and the University of Zurich.

FUNDING

This study was funded by the collaboration between the Infectious Diseases Institute Makerere University, and the University of Zurich, supported by Abbvie, Bristol Myers Squibb, Gilead Sciences, Janssen, Lunge Zürich, Merck, Shimadzu, Swiss HIV Cohort Study, and Viiv Healthcare. Genetic analyses were performed through internal funding available at the University of Infectious Diseases, Department of Medical Sciences, University of Torino.

CONFLICT OF INTEREST

A.C. and G.D.P. received research grants from Viiv Healthcare and consultancy fees/speakers’ honoraria from Gilead, MSD, Janssen-Cilag, and Viiv Healthcare. All other authors have no conflict to declare. J.F. is a member of the Federal Commission for Sexual Health and also received research and unrestricted grants from Gilead, Janssen, Merck, and Viiv Healthcare.

AUTHOR CONTRIBUTIONS

A.C. and I.M. wrote the manuscript. J.C., C.S.-W., A.v.B., B.C., J.F., and M.L. designed the research. J.C. and G.T. performed the research. A.C., I.M., and G.D.P. analyzed the data. J.C. and G.D.P. contributed new reagents/analytical tools.

© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics


